Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Cash from Investing Activities (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Cash from Investing Activities for 14 consecutive years, with $27.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities rose 21.1% year-over-year to $27.6 million, compared with a TTM value of $111.2 million through Dec 2025, up 809.85%, and an annual FY2025 reading of $111.2 million, up 809.85% over the prior year.
  • Cash from Investing Activities was $27.6 million for Q4 2025 at Fate Therapeutics, up from $21.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $80.4 million in Q3 2022 and bottomed at -$471.9 million in Q1 2021.
  • Average Cash from Investing Activities over 5 years is $3.9 million, with a median of $25.1 million recorded in 2023.
  • The sharpest move saw Cash from Investing Activities crashed 2084.89% in 2021, then surged 3036.37% in 2022.
  • Year by year, Cash from Investing Activities stood at $71.3 million in 2021, then dropped by 25.49% to $53.1 million in 2022, then decreased by 14.61% to $45.4 million in 2023, then plummeted by 49.69% to $22.8 million in 2024, then grew by 21.1% to $27.6 million in 2025.
  • Business Quant data shows Cash from Investing Activities for FATE at $27.6 million in Q4 2025, $21.3 million in Q3 2025, and $19.6 million in Q2 2025.